Standard treatment for glioblastoma (GBM) is surgery followed by radiotherapy and chemotherapy, often with the chemotherapeutic agent temozolomide. However, this treatment is not curative. In this issue, Li and colleagues uncover a novel circuit regulating GBM cell resistance to temozolomide that involves exosome-mediated transfer of the long noncoding RNA (lncRNA) lnc-TALC (temozolomide-associated lncRNA in glioblastoma recurrence) to microglial cells. The results provide new targets for therapeutics that could help overcome resistance to temozolomide.

See related article by Li et al., p. 1383. (3).

You do not currently have access to this content.